✦ LIBER ✦

Prognostic Utility of the Prostate Specific Antigen (PSA) Value 4-5 Years After 125I Brachytherapy

✍ Scribed by Lo, A.; Morris, W.; La Pointe, V.; Hamm, J.; Pickles, T.; Keyes, M.; McKenzie, M.; Spadinger, I.

Book ID: 122191446
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 62 KB
Volume: 87
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2013.06.929

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Permanent125I-seed prostate brachytherap

Permanent125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

✍ Renaud Mazeron, Agathe Bajard, Xavier Montbarbon, Frédéric Gassa… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 266 KB

Re: The Value of Serial Prostate Specifi

Re: The Value of Serial Prostate Specific Antigen Determinations 5 Years After Radiotherapy

✍ McKenzie, Michael R. 📂 Article 📅 1995 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 354 KB

In Reply: Re The Value of Serial Prostat

In Reply: Re The Value of Serial Prostate Specific Antigen Determinations 5 Years After Radiotherapy

✍ Stamey, T.A.; Ferrari, M.K.; Schmid, H.-P. 📂 Article 📅 1995 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 197 KB

Prostate-Specific Antigen at 4 to 5 Year

Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival

✍ Lo, Andrea C.; Morris, W. James; Lapointe, Vincent; Hamm, Jeremy; Keyes, Mira; P 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 375 KB

UP-02.151 Confusion of the PSA Rebound P

UP-02.151 Confusion of the PSA Rebound Phenomenon After I-125 Prostate Brachytherapy: A Cohort Study of Minimum 3-Year Follow-Up

✍ C. Casu; M. Angeles Cabeza; A. Rodriguez Antolin; A. Bartolomé; J. Romero Otero; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Calculated prostate carcinoma volume : T

Calculated prostate carcinoma volume : The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter

✍ Anthony V. D'Amico; Richard Whittington; Irving Kaplan; Clair Beard; Delray Schu 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Background: In this study, the authors evaluated whether a clinically relevant stratification of prostate specific antigen (psa) failure free survival (bned) after definitive local therapy could be made for patients with prostate carcinoma clinically classified as t1 or t2 and pretreatment psa l